27 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
of Lilly, visited POINT’s site in Toronto, Canada, during which representatives of Lilly and POINT toured the POINT Institute for Radioligand Innovation
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
of Lilly, visited POINT’s site in Toronto, Canada, during which representatives of Lilly and POINT toured the POINT Institute for Radioligand Innovation … Innovation.
Marschall S. Runge, M.D., Ph.D.*
Dr. Runge has served as a director of Lilly since 2013. Dr. Runge has served as executive vice president
SC14D9C
EX-99.7
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
5:24pm
agreed to be acquired by Lilly. We are excited to see our pipeline benefit from Lilly’s commitment to oncology, its rich history of innovation and its deep
ARS
qryfu vl7o2kbg5td
1 May 23
Annual report to shareholders
1:52pm
424B3
lf22dxe 9a0f2twdq
11 Jul 22
Prospectus supplement
4:32pm
POS AM
zcvpf
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
424B3
d2vy3zt00txl9cb4lcm
31 Mar 22
Prospectus supplement
11:42am
POS AM
4lcasz
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
EX-99.1
prwijyo4l
25 Feb 22
Prospectus supplement
8:39am
8-K
EX-99.1
5aelp
25 Feb 22
Regulation FD Disclosure
8:38am
8-K
EX-99.1
j4o4crb4 9c6nulpp
19 Nov 21
Regulation FD Disclosure
8:09am
424B3
h33v eh5jtzh
5 Aug 21
Prospectus supplement
4:26pm
S-4/A
EX-10.14
2p8m0u77q c9ce68p51
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.14
m7374cki
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
425
EX-99.1
56y ntqsu
15 Mar 21
Business combination disclosure
8:20am
8-K
EX-99.1
wfx11x1w n9
15 Mar 21
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
8:19am